Fuji Film Holdings announced on the 13th that it will invest 130 billion yen (roughly equivalent to $1.08 billion) to acquire Toyama Chemical Industry Co., Ltd., a mid-sized pharmaceutical company, marking its official entry into the healthcare sector. This strategic move is part of Fuji Film's broader plan to diversify its business and leverage its technological expertise in new markets.
According to Kyodo News, on the same day, Fuji Film, Toyama Chemical, and Taisho Pharmaceutical jointly announced that Fuji Film will acquire 66% of Toyama Chemical's shares through a public stock purchase. The remaining 34% will be retained by Daisaku Pharmaceutical, the current major shareholder. The three companies will work closely together to enhance their collaboration in research, development, and commercialization of medical products.
Fuji Film has previously been involved in various medical-related fields, including image processing, endoscopes, and other medical devices tied to its core film technology. With this acquisition, the company aims to fully establish itself in the pharmaceutical industry. The goal is to expand its pharmaceutical sales to more than three times the current level within the next decade, eventually reaching a scale of 1 trillion yen.
Toyama Chemical has faced financial difficulties in recent years, recording a loss of 8.7 billion yen in fiscal year 2006 due to rising R&D costs and intense market competition. By partnering with Fuji Film, the company expects to gain the necessary capital and resources to support future drug development and improve its overall performance.
This acquisition not only strengthens Fuji Film’s position in the healthcare industry but also signals a bold shift in its long-term strategy, reflecting the growing importance of biotechnology and pharmaceuticals in the global economy.
JIANGMEN PRO-TAYLOR REFRIGERATION CO., LTD. , https://www.protaylor.com